Home Self Admin denied as experimental or investigational by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Home Self-Administration as Experimental — and How to Appeal

An "experimental or investigational" denial on home self-administration means Humana has determined, under its coverage criteria, that the specific home delivery route or device lacks sufficient evidence of safety and efficacy to qualify as a covered benefit. This denial type often arises when a drug is FDA-approved for self-injection or subcutaneous administration but the plan's medical policy has not yet been updated to reflect the approved indication, or when the home delivery system (e.g., a wearable infusor or autoinjector) is newer than the policy.

### Why This Denial Is Appealable

If the FDA has approved the drug and the administration route for the patient's indication, the "experimental" label is factually contestable. FDA approval is a threshold finding that the therapy is safe and effective. Humana's internal experimental-or-investigational policy cannot override an FDA-approved indication, and many state external-review laws explicitly require reviewers to consider FDA approval status. The appeal should document the FDA-approval status clearly and contrast it with the plan's outdated or overly broad policy language.

### Federal Appeal Rights

• Internal appeal: File within the timeframe on the denial notice. Humana must issue a decision within 30 days for standard pre-service appeals.
• External review (ACA §2719 / ERISA §503): Experimental-or-investigational denials are among the most common categories sent to external review, and independent reviewers frequently overturn them when FDA approval exists. File for external review within four months of the final internal denial.
• Expedited review: Available if the standard process would seriously jeopardize health; decision typically within 72 hours.

### Documentation to Gather

1. FDA approval documentation: A copy of the relevant FDA approval or labeling for the drug and administration route, confirming the home self-administration method is within the approved indication. 2. Prescriber medical-necessity letter: A letter explaining why home self-administration is appropriate for this patient and citing the FDA-approved prescribing information. 3. Published professional society guidance: Reference the relevant clinical guideline organization (e.g., the applicable specialty society) that supports home self-administration for stable patients, without citing specific trial statistics. 4. Humana's experimental policy: Obtain Humana's current experimental-or-investigational coverage policy and identify specifically which criterion the plan claims is unmet. Respond to each criterion individually. 5. Clinical status documentation: Chart notes demonstrating the patient meets any clinical stability or training requirements.

### Criteria-Mapping Structure

List each criterion from Humana's experimental-or-investigational policy that the plan applied to deny coverage. For each criterion, provide the corresponding evidence (FDA label excerpt, chart note, prescriber letter) that demonstrates the criterion is met or that the criterion does not apply because FDA approval already addresses it. A point-by-point rebuttal is more effective than a narrative-only appeal.

Always verify current FDA approval status and Humana's most recent coverage policy before filing.